Galapagos NV (GLPG) Actualités

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the...

Galapagos receives transparency notification from EcoR1 Capital

Mechelen, Belgium; 30 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ:...

Galapagos receives transparency notification from EcoR1 Capital

Mechelen, Belgium; 16 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ:...

Galapagos receives transparency notification from FMR LLC

Mechelen, Belgium; 3 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SC 13D - General Statement of Acquisition of Beneficial Ownership

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Galapagos receives transparency notification from FMR LLC

Mechelen, Belgium; 20 August 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ:...

Galapagos reports half-year 2024 financial results and provides second quarter business update

Executing on our Forward, Faster strategy with strong progress in a pivotal year, focused on delivering...

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]